ARTICLE | Clinical News
Supernus reports adult ADHD data
March 12, 2011 12:57 AM UTC
Supernus Pharmaceuticals Inc. (Rockville, Md.) said thrice-daily oral SPN-812 for five weeks was well tolerated and met the primary endpoint of safety in a Phase IIa trial to treat 52 adults with ADHD...